Navigation Links
Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income
Date:7/29/2008

d Six Months Ended

June 30, June 30,

Income Statement: 2008 2007 2008 2007

Net sales $181,184 $160,366 $338,840 $304,217

Cost of goods sold

(exclusive of depreciation

and amortization) 88,223 78,945 167,292 151,494

Selling, general and

administrative 67,285 59,714 127,492 114,872

Depreciation and

amortization 4,289 3,878 8,470 7,626

Income from operations 21,387 17,829 35,586 30,225

Interest expense 8,045 9,125 16,303 18,465

Income before taxes 13,342 8,704 19,283 11,760

Provision for income taxes 5,337 3,612 7,713 4,884

Net income 8,005 5,092 11,570 6,876

Less preferred stock

dividend - Series A

Convertible Preferred

Stock 5,254 416 5,670 833

Net income applicable to

common stock $2,751 $4,676 $5,900 $6,043

Basic Per Common Share Data:

Net income $0.12 $0.21 $0.26 $0.27

Shares used to compute

basic per common share

amounts 23,017,282 22,399,292 22,949,127 22,295,606

Diluted Per Common Share Data:

Net income $0.11 $0.17 $0.24 $0.23

Shares used to compute

diluted per common share

amounts 24,208,631 30,049,735 24,121,834 29,908,304

Three Months Ended Six Months Ended

Pro-forma: June 30, 2008 June 30, 2008

Net income applicable to

comm
'/>"/>

SOURCE Hanger Orthopedic Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Hanger Orthopedic Group, Inc. Receives Positive Outlook from Standard & Poors Rating Services
2. Hanger Orthopedic Group, Inc. Announces Second Quarter 2008 Earnings Release Conference Call
3. Hanger Orthopedic Group, Inc. Announces an 11% Sales Increase and a 35% Increase in EPS to $0.23 for the Quarter Ended December 31, 2007, Compared to $0.17 in the Prior Year
4. Hanger Orthopedic Group, Inc. Announces Senior Leadership Succession Plan and Reaffirms Guidance
5. Hanger Orthopedic Group, Inc. Announces 2007 Year-End Earnings Release Conference Call
6. Hanger Orthopedic Group, Inc. Announces Three Acquisitions Totaling Over $3.5 Million of Annual Net Revenue
7. Infor-Med, Inc. Announces New Praxis EMR Version 4 with The Praxis Knowledge Exchanger(R)
8. Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007
9. Central DuPage Hospitals Orthopedics Ranks in U.S. News Media Groups 2008 Edition of Americas Best Hospitals for the Second Consecutive Year
10. Three Industry Veterans Join Ascension Orthopedics
11. Swedish Orthopedic Institute Opens in Seattle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Recently, ZKB filed another federal ... Division (Case No. 3:15-cv-00397) involving the Implanon® contraceptive implant . , As ... their Implanon® implants, inability to locate the implants, unsuccessful and invasive attempts at ...
(Date:7/31/2015)... ... 2015 , ... Florida Hospital Tampa has started treating select ... targeted delivery of fluids to selected sites in the peripheral vascular system. Patients ... the device that provides direct, local delivery of chemotherapy to the pancreas. This ...
(Date:7/31/2015)... ... , ... Awarded to only the Top 10 hair transplant practices in the ... latest recipients of the Center of Clinical Excellence for ARTAS Robotic Hair Transplantation ... the science of hair transplant. , Parsa Mohebi Hair Restoration is known worldwide for ...
(Date:7/31/2015)... ... July 31, 2015 , ... Healthpointe , a ... redesigned website at Healthpointe.net. The new website will feature a sleek and streamlined ... serves to provide smoother interactions between patients and the Healthpointe clinics and ensures ...
(Date:7/31/2015)... ... July 31, 2015 , ... The ... Karmanos Center for Natural Birth . The Karmanos Center for Natural Birth ... childbirth experience. With nurses and caregivers that are trained in holistic birth approaches, ...
Breaking Medicine News(10 mins):Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Healthpointe Announces Newly Redesigned Website 2
... ... been associated with numerous warnings. If YAZ®/Yasmin® side effects have resulted in ... ... -- The widely-used oral contraceptive YAZ® (alternatively named Yasmin® ) has recently been targeted ...
... 11 Emdeon Inc. (the "Company") today announced the pricing of ... common stock at a price of $15.50 per share. Of the ... were offered by selling stockholders. The shares will be listed on ... the extent that the underwriters sell more than 23,700,000 shares of ...
... , , , ... to repay more than $500 million in benefits that were unlawfully ... part of a class action settlement preliminarily approved by U.S. District ... were suspended or denied between 2000 and 2006 will be notified ...
... , LIONVILLE, Pa., Aug. 11 West ... Federici, Chief Financial Officer, and Michael Anderson, Vice President, Treasurer and Head ... Ideas" Summer Conference on Tuesday, August 18, 2009 in White Plains, NY. ... presentation or a webcast, Mr. Federici and Mr. Anderson will present a ...
... , , , ... Web site , , CHICAGO, Aug. 11 ... o to/publicsurvey and become eligible to win a ... Web site, ADA.org. , , ADA.org provides news and information ...
... , , ATLANTA, Aug. 11 Sean Carroll, CEO ... , has been appointed to serve as a board member of the ... AHI M A ). The ... 1962, is a non-profit organization that provides development, research and scholarships for ...
Cached Medicine News:Health News:Ohio Law Firm Warns of Birth Control Pill YAZ/Yasmin Side Effects Lawsuits 2Health News:Ohio Law Firm Warns of Birth Control Pill YAZ/Yasmin Side Effects Lawsuits 3Health News:Ohio Law Firm Warns of Birth Control Pill YAZ/Yasmin Side Effects Lawsuits 4Health News:Emdeon Inc. Prices Initial Public Offering of Class A Common Stock at $15.50 Per Share 2Health News:Emdeon Inc. Prices Initial Public Offering of Class A Common Stock at $15.50 Per Share 3Health News:Emdeon Inc. Prices Initial Public Offering of Class A Common Stock at $15.50 Per Share 4Health News:Government Stops Unlawful Social Security Suspensions; Agrees to Repay More Than Half a Billion in Back Benefits 2Health News:American Dental Association Web Survey Offers Chance at $150 Gift Certificate 2Health News:Webmedx Announces That CEO Sean Carroll Has Been Appointed to the AHIMA Foundation Board of Directors 2
(Date:7/30/2015)... 2015 Eisai Inc. announced today that regulatory ... States , European Union and Japan ... for eribulin, for the treatment of patients with inoperable ... for advanced or metastatic disease. These ... global Phase 3 clinical trial (Study 309), which met ...
(Date:7/30/2015)... 30, 2015 Future Market Insights ... "Continuous Glucose Monitoring Systems Market: Global Industry Analysis and ... the global continuous glucose monitoring systems market was valued ... to reach US$ 788.4 Mn by 2020, registering a ... 2020. Global continuous glucose monitoring systems market ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, Inc. ... second Phase III clinical study for Ozenoxacin, a ... Medimetriks owns the exclusive U.S. rights to Ozenoxacin ... conducted at 44 centers with an emphasis on ... aged 2 months and older with a clinical ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... Cardiovascular Safety and Potential Benefits of Exenatide to be Prospectively ... June 8 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... ) today announced results from a meta-analysis of cardiovascular (CV) ... with BYETTA(R) (exenatide) injection use compared to a pooled comparator ...
... Dose Optimization of Pre-Clinical Otelixizumab Surrogate , ... a biopharmaceutical company engaged in the discovery and ... presented results from a pre-clinical dose-optimization study conducted ... monoclonal antibody, otelixizumab, at the 69th Scientific Sessions ...
Cached Medicine Technology:Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 2Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 3Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 4Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 5Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 6Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 2Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 3
PTC-100 cycler with gold/silver block with Hot Bonnet heated lid, holds one 96-well V-plate or96x0.2ml tubes...
MBS 0.2 ml satellite block unit with height adjusting heated lid, 96 well standard block - holds 96 x 0.2ml tubes or 1 x 96 well plate (includes tube thermistor)...
PxE thermal Cycler. 0.2ml, 96 well block holds 96 tubes or 1 x 96 well plate. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced reaction times. User f...
... (PxE) is a licensed 96 well PCR machine, ... for money thermal cycling. It is built ... in manufacturing and retains a high level of ... products in the range. The combination of ...
Medicine Products: